Qiagen NV (NASDAQ:QGEN) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 0.05%.
Qiagen NV Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 17.39% to $0.27 in the quarter versus EPS of $0.23 in the year-earlier quarter.
Revenue: Rose 2.99% to $316.4 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Qiagen NV reported adjusted EPS income of $0.27 per share. By that measure, the company beat the mean analyst estimate of $0.23. It beat the average revenue estimate of $312.3 million.
Quoting Management: “QIAGEN delivered growth across all regions in the second quarter of 2013 despite challenging economic conditions, particularly given the funding concerns for life sciences research in the United States and Europe. Our focus on accelerating innovation and growth is delivering value with improving results in Molecular Diagnostics, Pharma and Academia,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “Multiple growth drivers are propelling QIAGEN forward, including the QuantiFERON-TB latent tuberculosis test, our industry-leading Personalized Healthcare portfolio and the successful QIAsymphony automation platform. We are moving ahead with plans to provide a unique solution for targeted areas of next-generation sequencing with a differentiated GeneReader sample-to-result workflow that integrates our rapidly expanding portfolio of GeneRead NGS assay panels and Ingenuity’s gold-standard biological data interpretation solutions. We are completing the transformation of QIAGEN through an efficiency project that has strengthened our capabilities to capture growth opportunities in a fast-changing environment. Our conviction about QIAGEN’s growth prospects is backed by a new $100 million share repurchase program. Based on the solid results in the first half of the year, QIAGEN continues to be well-positioned to achieve its goals for 2013.”
Key Stats (on next page)…
Revenue increased 4.22% from $303.58 million in the previous quarter. EPS increased 35% from $0.20 in the previous quarter.
Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.26 and has not changed. For the current year, the average estimate has moved down from a profit of $1.08 to a profit of $1.05 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)